Answers are grounded in this paper and cite their sources.
There is mounting evidence that patient-reported outcomes (PROs) provide significantly more toxicity and symptom data than clinician or Common Terminology Criteria of Adverse Events (CTCAE) assessments. The Food and Drug Administration recently defined a PRO as a measurement of any aspect of a patient's health status that comes directly from the patient, without interpretation of the patient's responses by a clinician or research associate. asch et al have pioneered the adaptation of CTCAE into PRO measurements. In this issue, they discuss the feasibility of longterm toxicity monitoring using an electronic, patient self-reported, modified version of the CTCAE. They have carefully laid the groundwork by adapting the CTCAE symptom items into lay language and selecting salient items particular to the patients studied with thoracic malignancies receiving chemotherapy. This report documented that the CTCAE-PRO version is indeed highly feasible across sex, age, education level, baseline performance status, disease type and stage, or chemotherapy regimen. he work of Basch et al 4 is more than just an interesting exercise. It is, in fact, the beginning of a process that may change the way in which toxicity in cancer clinical trials is measured and reported. The CTCAE has been a useful tool; yet, as with most tools, improvements are desired. There are several flaws in the CTCAE that have long been recognized, and there is recent progress in addressing some of these issues. One issue is the inability to summarize severity of both acute and long-term toxicity. A novel method to better capture the burden of such toxicity experienced by patients on clinical trials has recently been published. nother drawback to the CTCAE is that there is currently no standardized training for the implementation of this tool. This is highly problematic because the grading of toxicities is highly variable as a result of the differences in training and education related to patient assessments of those who use the tool (such as research associates, only some of whom may be nurses and many of whom may be from various, even nonmedical, backgrounds). In addition, the way in which CTCAE is recorded varies among institutions. Whereas some institutions may have the research associate meet with and assess the patient, other institutions have the research associates abstract the medical record. This latter approach means that the research associate must interpret the clinician's own interpretation of the patient's experience. Each iteration takes us further from the scientific rigor of assessing the patient's actual experience with toxicities.
No takes yet. Share an insight, caveat, or question.
Deborah Watkins Bruner (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: